Supported by

Tricuspid / Pulmonary valve

Latest tricuspid content in interventional cardiology - research, practice, and education

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

492 results

Repair vs. replacement for the treatment of tricuspid valve disease

27 Nov 2022 – From PCR London Valves 2022

Watch this session on tricuspid valve disease to learn more about its current modes of treatment (including new and emerging devices), to understand which patients are the best candidates for this procedure and to explore the challenges that may be encountered during it.

Repair vs. replacement for the treatment of tricuspid valve disease

The right valves for the right ventricle: Venus MedTech tricuspid and pulmonary replacement systems

27 Nov 2022 – From PCR London Valves 2022

In this session from PCR London Valves 2022, discover the new Venus MedTech technology for tricuspid and pulmonary valve replacement, and a review of the clinical indications, selection criteria and procedural details.

The right valves for the right ventricle: Venus MedTech tricuspid and pulmonary replacement systems

Therapy of valvular heart diseases: a patient-centred innovation journey

27 Nov 2022 – From PCR London Valves 2022

Join a team of experts as they review together the complete spectrum of valvular heart disease and ways in which we can manage it using emerging novel technologies.

Therapy of valvular heart

Twenty years of progress - What we have achieved - LIVE case

27 Nov 2022 – From PCR London Valves 2022

  • Part 1: TAVI by axillary access (Live)
    An 80-year-old female with peripheral arterial disease presents a symptomatic severe aortic stenosis with small annulus and preserved LV function.
    The operators implant, by axillary access, an Evolut pro 26 mm, on general anaesthesia, with predilatation (Balloon 18 mm) and post-dilatation...
Twenty years of progress - What we have achieved

TRISCEND, ACURATE neo2, the LuX-Valve System: Top Late-Breaking Trials from PCR London Vaves 2022

27 Nov 2022 – From PCR London Valves 2022

Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions and learn more about the latest evidence evidence concerning new transcatheter valve devices, emerging innovative devices as well as highlighted content from the EuroIntervention journal.

Top Late-Breaking Trials

CLASP II TR, TriBAND, bRIGHT: Late-Breaking Trials on tricuspid intervention

27 Nov 2022 – From PCR London Valves 2022

Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions in this session: the CLASP II TR on transcatheter tricuspid valve repair, the TriBAND study one-year outcomes on transcatheter tricuspid annular reduction, and the bRIGHT trial on real-world outcomes for TEER.

Tricuspid - Late-Breaking Trials

Acute kidney injury following tricuspid transcatheter edge-to-edge repair

17 Oct 2022

Although tricuspid regurgitation has for a long time been “the forgotten valve”, recently there has been a rising awareness of the disease with several important studies investigating its pathophysiology and treatment.

Antonio Mangieri

Reviewer

Antonio Mangieri
Alessandro Sticchi

Reviewer

Alessandro Sticchi
Acute kidney injury following tricuspid transcatheter edge-to-edge repair

1-year outcomes of Cardioband Tricuspid Valve Reconstruction System early feasibility study

10 Oct 2022

Jonathan Curio

Reviewer

Jonathan Curio
Dr. Gilbert Tang

Reviewer

Gilbert Tang
1-year outcomes of Cardioband Tricuspid Valve Reconstruction System early feasibility study

Treatment of severe tricuspid regurgitation - Session with LIVE case

07 Oct 2022 – From AICT-AsiaPCR 2022

Watch the LIVE case management of an 84-year-old male patient, diabetic, hypertensive, with previous PCI on LAD and ICD, permanent AF, and exertional dyspnea for 6 months and learn more about severe tricuspid regurgitation pathology and treatment.

Treatment of severe tricuspid regurgitation

Abstracts - Coronary interventions - Session 4

07 Oct 2022 – From AICT-AsiaPCR 2022